Biophotonics

Funding Opportunity ID: 287189 Opportunity Number: PD-16-7236 Opportunity Title: BiophotonicsOpportunity Category: DiscretionaryOpportunity Category Explanation: Funding Instrument Type: GrantCategory of Funding Activity: Science and Technology and other Research and DevelopmentCategory Explanation: CFDA Number(s): 47.041Eligible Applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"Additional Information on Eligibility: Agency Code: NSFAgency Name: National Science FoundationPosted Date: Aug 09, 2016Close Date: Oct 20, 2016Last Updated Date: Aug 09, 2016Award Ceiling: Award Floor: Estimated Total Program Funding: $6,600,000Expected Number of Awards: Description: The goal of the Biophotonicsprogram is to explore the research frontiers in photonics principles, engineering and technology that are relevant for critical problems in fields of medicine, biology and biotechnology. Fundamental engineering research and innovation in photonics is required to lay the foundations for new technologies beyond those that are mature and ready for application in medical diagnostics and therapies. Advances are needed in nanophotonics, optogenetics, contrast and targeting agents, ultra-thin probes, wide field imaging, and rapid biomarker screening. Low cost and minimally invasive medical diagnostics and therapies are key motivating application goals. Research topics in thi...
Source: Grants.gov - Category: Research Tags: Science and Technology and other Research and Development Source Type: funding

Related Links:

Publication date: Available online 18 November 2019Source: Cancer GeneticsAuthor(s): Michael Evenson, Chunyu Cai, Vishwanathan Hucthagowder, Samantha McNulty, Julie Neidich, Shashikant Kulkarni, Sonika DahiyaAbstractEpendymomas are neuroepithelial tumors that differentiate along the ependymal cell lineage, a lining of the ventricles of the brain and the central canal of the spinal cord. They are rare in adults, but account for 9% of brain tumors in children, where they usually have an aggressive course. Efficient stratification could lead to improved care but remains a challenge even in the genomic era. Recent studies prop...
Source: Cancer Genetics - Category: Cancer & Oncology Source Type: research
The ability of self-replicating oncolytic viruses (OVs) to preferentially infect and lyse cancer cells while stimulating anti-tumor immunity of the host strongly indicates its value as a new field of cancer therapeutics to be further explored. The emergence of Zika virus (ZIKV) as a global health threat due to its recent outbreak in Brazil has caught the attention of the scientific community and led to the discovery of its oncolytic potential for the treatment of glioblastoma multiforme (GBM), the most common and fatal brain tumor with poor prognosis. Herein, we evaluate the neurotropism of ZIKV relative to the receptor ty...
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
HOUSTON, Nov. 19, 2019 -- (Healthcare Sales &Marketing Network) -- CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("Company"), a biotechnology company specializing in the development of novel treatments for brain tumors, completed an agreement with H... Biopharmaceuticals, Licensing CNS Pharmaceuticals, Houston Pharmaceuticals, Berubicin
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
Charlie Card, of Newcastle, began missing school this year complaining of not feeling well. His father, Gary Card, 43, has urged parents to never ignore their children.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
CONCLUSIONS: Our studies demonstrated that GLO1 was highly expressed in glioma tissues and significantly correlated with the poor prognosis of glioma patients. It indicated that GLO1 might serve as a new prognostic predictor and therapeutic target for glioma treatment. PMID: 31738028 [PubMed - as supplied by publisher]
Source: Journal of Neurosurgical Sciences - Category: Neurosurgery Tags: J Neurosurg Sci Source Type: research
PALO ALTO, Calif., Nov. 18, 2019 /PRNewswire/ -- Varian (NYSE: VAR) today announced the South Florida Proton Therapy Institute (SFPTI), a Proton International facility, on the campus of Delray Medical Center, has treated its first patient utilizing the Varian ProBeam® Compact single-room proton therapy system. Proton therapy can be used to treat many types of tumors including in the brain, head and neck, central nervous system and lung, and more precisely targets cancer cells...This story is related to the following:Radiotherapy Systems
Source: Industrial Newsroom - Health, Medical and Dental Supplies - Category: Medical Devices Source Type: news
Ollie Gardiner's family raised money to treat his brain tumour but he died aged 13 after a relapse.
Source: BBC News | Health | UK Edition - Category: Consumer Health News Source Type: news
ConclusionNon-US and single systemic therapy studies are more commonly associated with strict exclusion of brain metastasis in ES-SCLC trials. The strict exclusion of brain metastases in clinical trials has remained relatively constant for the past few decades.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
As an oncologist, I want information to help me speak with the patient about her particular circumstances, with that discussion couched in our knowledge of the role of irradiation and other modalities in the management of breast cancer brain metastases.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Gray Zone Source Type: research
A 70-year-old female patient with a history of locally advanced breast cancer presented with a 2-month duration of persistent gait imbalance. Ten years earlier, she initially received a diagnosis of an invasive ductal carcinoma of the right breast, triple negative, treated with mastectomy and axillary lymph node dissection, followed by adjuvant chemotherapy and postmastectomy radiation therapy. She had been followed up without evidence of disease until the present time. Magnetic resonance imaging of the brain demonstrated a lobulated enhancing mass measuring 3.6  × 2.4 × 3.6 cm involvin...
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Gray Zone Source Type: research
More News: Academia | Biology | Biotechnology | Brain | Brain Cancers | Cancer | Cancer & Oncology | Cardiology | Career Development | Conferences | Funding | Genetics | Grants | Heart | Nanotechnology | Neurology | Neuroscience | Opthalmology | Research | Science | Study | Workshops